Merck sell-off creates buying opportunity, says Argus Argus predicts that Merck's stock will be boosted by positive pipeline news, particularly regarding its osteoporosis drug odanacatib The firm expects the company to resume growing in 2014 and it maintains a Buy rating on the shares.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
FDA approves Belsomra sleep drug The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.